Bio Path Holdings Stock Today
| BPTH Stock | USD 2.69 0.23 7.88% |
Performance0 of 100
| Odds Of DistressOver 84
|
Bio Path is trading at 2.69 as of the 24th of April 2024. This is a -7.88% down since the beginning of the trading day. The stock's open price was 2.92. Bio Path has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Bio Path Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of March 2024 and ending today, the 24th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of March 2008 | Category Healthcare | Classification Health Care |
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. Bio-Path Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 1.57 M outstanding shares of which 67.41 K shares are currently shorted by private and institutional investors with about 1.34 trading days to cover. More on Bio Path Holdings
Moving against Bio Stock
| 0.83 | ELEV | Elevation Oncology Financial Report 20th of May 2024 | PairCorr |
| 0.8 | VKTX | Viking Therapeutics Earnings Call Today | PairCorr |
| 0.78 | XFOR | X4 Pharmaceuticals Financial Report 2nd of May 2024 | PairCorr |
| 0.76 | NRSNW | NeuroSense Therapeutics | PairCorr |
| 0.6 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.58 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
| 0.54 | ACB | Aurora Cannabis Trending | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 10th of May 2024
Bio Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Bio Path's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Bio Path or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | Peter Nielsen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Bio Path report their recommendations after researching Bio Path's financial statements, talking to executives and customers, or listening in on Bio Path's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Bio Path Holdings. The Bio consensus assessment is calculated by taking the average forecast from all of the analysts covering Bio Path. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators obtained from Bio Path's historical financial statements, Bio Path Holdings is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Bio Path Holdings is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bio Path's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Bio Path's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bio Path's financial leverage. It provides some insight into what part of Bio Path's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bio Path Holdings (BPTH) is traded on NASDAQ Exchange in USA. It is located in 4710 Bellaire Boulevard, Bellaire, TX, United States, 77401 and employs 10 people. Bio Path is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.2 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bio Path's market, we take the total number of its shares issued and multiply it by Bio Path's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Bio Path Holdings conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.57 M outstanding shares of which 67.41 K shares are currently shorted by private and institutional investors with about 1.34 trading days to cover.
Bio Path Holdings currently holds about 17.02 M in cash with (11.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38.
Check Bio Path Probability Of Bankruptcy
Ownership AllocationAlmost 98.0 percent of Bio Path outstanding shares are held by general public with 0.1 (percent) owned by insiders and only 1.8 % by other corporate entities.
Check Bio Ownership Details
Bio Stock Price Odds Analysis
Coming from a normal probability distribution, the odds of Bio Path jumping above the current price in 90 days from now is more than 94.0%. The Bio Path Holdings probability density function shows the probability of Bio Path stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Bio Path Holdings has a beta of -1.1014 suggesting Additionally, bio Path Holdings has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Bio Path to move above the current price in 90 days from now is more than 94.0 (This Bio Path Holdings probability density function shows the probability of Bio Stock to fall within a particular range of prices over 90 days) .
Bio Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Bio Path that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bio Path's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bio Path's value.| Instituion | Recorded On | Shares | |
| Bank Of America Corp | 2023-12-31 | 152 | |
| Hanson Mcclain Inc | 2023-12-31 | 150 | |
| Wells Fargo & Co | 2023-12-31 | 95.0 | |
| Global Retirement Partners, Llc. | 2023-12-31 | 69.0 | |
| Royal Bank Of Canada | 2023-12-31 | 20.0 | |
| Advisor Group Holdings, Inc. | 2023-12-31 | 10.0 | |
| Warberg Asset Management Llc | 2023-12-31 | 0.0 | |
| Millennium Management Llc | 2023-12-31 | 0.0 | |
| Virtu Financial Llc | 2023-09-30 | 0.0 | |
| Vanguard Group Inc | 2023-12-31 | 270 K | |
| Geode Capital Management, Llc | 2023-12-31 | 110.4 K |
Bio Path Historical Income Statement
Bio Path Holdings Income Statement is one of the three primary financial statements used for reporting Bio's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Bio Path Holdings revenue and expense. Bio Path Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of now, Bio Path's Research Development is increasing as compared to previous years. The Bio Path's current Reconciled Depreciation is estimated to increase to about 198.9 K, while Depreciation And Amortization is projected to decrease to under 179.9 K. View More FundamentalsBio Stock Against Markets
Picking the right benchmark for Bio Path stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Bio Path stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Bio Path is critical whether you are bullish or bearish towards Bio Path Holdings at a given time. Please also check how Bio Path's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Bio Path without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Ceiling Movement Now
Price Ceiling MovementCalculate and plot Price Ceiling Movement for different equity instruments |
| All Next | Launch Module |
Bio Path Corporate Directors
Bio Path corporate directors refer to members of a Bio Path board of directors. The board of directors generally takes responsibility for the Bio Path's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Bio Path's board members must vote for the resolution. The Bio Path board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Mark Colonnese | Independent Director | Profile | |
| Heath Cleaver | Director | Profile | |
| Paul Aubert | Independent Director | Profile | |
| Douglas Morris | Co-Founder and Director | Profile |
How to buy Bio Stock?
Before investing in Bio Path, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Bio Path. To buy Bio Path stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Bio Path. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Bio Path stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Bio Path Holdings stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Bio Path Holdings stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Bio Path Holdings, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Bio Stock please use our How to Invest in Bio Path guide.
Already Invested in Bio Path Holdings?
The danger of trading Bio Path Holdings is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Bio Path is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Bio Path. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Bio Path Holdings is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Bio Stock analysis
When running Bio Path's price analysis, check to measure Bio Path's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Path is operating at the current time. Most of Bio Path's value examination focuses on studying past and present price action to predict the probability of Bio Path's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Path's price. Additionally, you may evaluate how the addition of Bio Path to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Bio Path's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (33.63) | Return On Assets (1.03) | Return On Equity (2.20) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.